http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Agenus (AGEN) Secures $7.5M Milestone Payment from Gilead Sciences, Inc. (GILD)
-
Agenus Milestone Triggers $7.5M Payment from Gilead
-
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
-
Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
-
Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
-
Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare
-
Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.
-
Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
-
Selexis Expands Strategic Immuno-Oncology Alliance with Agenus
-
Agenus Awarded Grant to Enable QS-21 Innovations
-
Agenus (AGEN), Gilead Sciences, Inc. (GILD) Announces Collaboration to Develop Immuno-Oncology Therapies
-
Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
-
Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
-
Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell
-
Agenus to Present at the 2018 Jefferies London Healthcare Conference
-
Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018
-
Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update
-
Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast
-
Agenus (AGEN) Reports Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
-
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
-
Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018
-
Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY
-
Agenus (AGEN) Closes $15 Million Partial Royalty Monetization With XOMA (XOMA)
-
Agenus Closes $15 Million Partial Royalty Monetization With XOMA
-
Agenus (AGEN) Secures $5M Milestone Payment from Incyte (INCY) for Initiation of Phase 1 Clinical Trial of INCAGN2385
-
Agenus Receives Milestone Payment from Incyte
-
AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA
-
Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City
-
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update
-
Incyte (INCY), Agenus (AGEN) Announce Amendment to Collaboration Agreement
-
Incyte and Agenus Amend Collaboration Agreement
-
Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine
-
Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
-
Cancer Immunotherapy ETF Celebrates One-Year Anniversary
-
Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)
-
Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
-
Agenus to Report Third Quarter 2015 Financial Results on October 27, 2015; Conference Call to Follow
-
Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital
-
Agenus to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
-
GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon® Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa
-
Agenus Reports Second Quarter 2015 Financial Results
-
Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1
-
Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow
-
Agenus to Webcast Annual Meeting of Stockholders
-
Agenus to Present at the 2015 JMP Securities Life Sciences Conference
-
Agenus Appoints C. Evan Ballantyne as Chief Financial Officer
-
Merck Extends Immuno-Oncology Collaboration with Agenus
-
Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
-
Agenus to Host Research and Development Day on May 14, 2015
-
NEJM Publishes Study Showing GSK’s Shingles Vaccine Containing Agenus’ QS-21 Stimulon® Adjuvant Provides over 97% Protection in People Over the Age of 50

